Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867887 | 0.82 | CYP1A2 (0.39) | ALOX5APFEN1GRIN1GRIN2B | |
| SCHEMBL11902852 | 0.79 | MAP4K4 (0.33) | ALOX5APFEN1 | |
| SCHEMBL15169486 | 0.76 | MPL (0.45) | MPLKMORIPK1 | |
| SCHEMBL868629 | 0.75 | PTGS2 (0.44) | GRIN1GRIN2B | |
| SCHEMBL11903355 | 0.75 | NPC1 (0.51) | KMO | |
| SCHEMBL11902833 | 0.75 | CYP1A1 (0.41) | PIK3CA | |
| SCHEMBL11903363 | 0.72 | CYP1A1 (0.39) | KMO | |
| SCHEMBL11903373 | 0.72 | CYP1A1 (0.39) | KMOS1PR1 | |
| SCHEMBL4875273 | 0.70 | MPL (0.58) | MPLPIK3CAPIK3CDALOX5APFEN1 | |
| SCHEMBL17476606 | 0.69 | NPC1 (0.35) | ALOX5APFEN1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | MPL 2845/4885PIK3CA 87/4885PIK3CD 215/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | MPL 2860/4885PIK3CA 106/4885PIK3CD 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.